Three phases in. $JST supply is not the same anymore. 🔥1,356,228,332 JST burned 📉13.70% removed from total supply 💎$60.03M in value And it doesn’t stop there. From accumulation → to execution → to finality. All on-chain. All verifiable. This isn’t an event. It’s a system.

New phase 2 trial findings published in The Lancet Diabetes & Endocrinology suggest burosumab treatment for X-linked hypophosphataemia (XLH) may begin in the first year of life. Unpick the findings in our latest article.

🚀 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗶𝘀 𝗹𝗶𝘃𝗲. 𝗧𝗵𝗲 𝗞𝗢𝗟 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗖𝗼𝗻𝘁𝗲𝘀𝘁 officially begins today as part of the 𝗧𝗲𝗿𝗺𝗠𝗮𝘅 𝗗𝗲𝗙𝗶 𝗥𝗲𝗻𝗮𝗶𝘀𝘀𝗮𝗻𝗰𝗲 𝗣𝗿𝗼𝗴𝗿𝗮𝗺: 𝗧𝗵𝗲 𝗚𝗿𝗲𝗮𝘁 𝗔𝘄𝗮𝗸𝗲𝗻𝗶𝗻𝗴. Top DeFi KOLs have published their strategies. Now it’s your turn to vote for them! 👉 Explore strategies & vote for your KOL:

BioVie $BIVI: SUNRISE-PD Phase 2b Trial Completes Last Patient Visit — Topline Parkinson's Data on Track for Q3 2026 $BIVI has completed the final patient evaluation visit in its SUNRISE-PD Phase 2b trial, a 57-patient, randomized, double-blind, placebo-controlled study evaluating bezisterim in early-stage Parkinson's disease patients who have not yet been treated with carbidopa/levodopa. The company is now entering the study closeout process, with topline results expected in Q3 2026. SUNRISE-PD was specifically designed to quantify the magnitude of bezisterim's therapeutic impact on motor function, sleep disorder, anxiety, depression, and cognitive slowness, with the explicit goal of finalizing the design for Phase 3 registrational trials. This readout is the blueprint decision point for the path to potential approval. In prior clinical work, bezisterim has shown signals of improved motor control, reduced neuroinflammation, and improved "morning on" symptoms in Parkinson's patients. Why Investors Should Be Watching: • Topline data catalyst in Q3 2026 • Results are designed to inform Phase 3 registrational trial design — this is a structural milestone, not just a data point • Bezisterim targets TNFα-mediated inflammation and insulin resistance, a differentiated mechanism in a disease space with significant unmet need • A recent KOL event featuring a Brown University neuropathologist reinforced the scientific rationale behind bezisterim's approach to neurodegeneration • Long COVID Phase 2 topline data also expected Summer 2026, providing a second near-term catalyst For investors tracking $BIVI, Q3 2026 is shaping up as a defining period — one readout that could set the Phase 3 course for bezisterim in Parkinson's, and a second from the Long COVID program arriving around the same time. Read the full announcement: $BIVI $SXTP $INAB $DMAC $BFRG $NSRX $CLDI $NXL $CNTB $LTRN $KYNB $ANIX